The efficacy and tolerability of changing regimen from recombinant human erythropoietin (rhuepo) to darbepoetin alfa in chronic hemodialysis patients

• In: Hospital Pharmacy Section - Posters
• At: Beijing (China) (2007)
• Type: Poster
• Poster code: HPS-P-104
• By: TSAI, Pin-Chin (E-DA HOSPITAL/I-SHOU UNIVERSITY, Kaohsiung, China Taiwan)
• Co-author(s): Liu, Hui-Pine (E-Da Hospital, I-Shou University, KAOHSIUNG, China Taiwan)
  Lin, Mei-Fang (E-Da Hospital, I-Shou University, KAOHSIUNG, China Taiwan)
  Chang, Min-Yu (E-Da Hospital, I-Shou University, KAOHSIUNG, China Taiwan)
  Wu, Chia-Chun (E-Da Hospital, I-Shou University, KAOHSIUNG, China Taiwan)
  Wang, Yu-Ting (E-Da Hospital, I-Shou University, KAOHSIUNG, China Taiwan)
  Hung, Shih-Yuan (E-Da Hospital, I-Shou University, KAOHSIUNG, China Taiwan)
  
• Abstract:

  Darbepoetin alfa is an improvement type of erythropoietic agent with a 3-fold longer elimination half-life than recombinant human erythropoietin (rHuEpo), which has been shown to allow less frequent dosing in the treatments of renal anemia. The objective of this study was to observe the efficacy and tolerability of shifting from rHuEpo-beta (Roche ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login